A Follow-On, Open-Label Trial To Assess Continued Safety Of And Adherence To The Dapivirine (25 Mg) Vaginal Ring-004 In Healthy, HIV-Negative Women
Phase of Trial: Phase III
Latest Information Update: 01 Sep 2017
At a glance
- Drugs Dapivirine (Primary)
- Indications HIV infections
- Focus Adverse reactions
- 22 Aug 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Dec 2018.
- 22 Aug 2017 Status changed from not yet recruiting to recruiting.
- 11 Aug 2016 New trial record